ArticleDrug design, development and therapy2026
Metabolomics Reveals Potential Biomarkers for Early Detection of irAEs in ICI-Treated Patients.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify predictive metabolic biomarkers for immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs) using metabolomics, supporting early detection and intervention. Patients and Methods: Fifty-five ICI-treated cancer patients from Changxing People's Hospital were divided into irAEs-positive (34 cases) and irAEs-negative (21 cases) groups after 12-month follow-up. Pretreatment serum samples were analyzed by untargeted UPLC-MS metabolomics. PCA, OPLS-DA, and KEGG pathway enrichment were used to screen differential metabolites and key pathways. Results: Seventy significant differential metabolites (eg, ursodeoxycholic acid, uric acid) were identified. β-Alanine metabolism, pentose phosphate pathway, and coenzyme A biosynthesis were closely correlated with irAEs. Five metabolites showed AUC 0.7-0.9 with favorable predictive performance. Conclusion: Metabolomics reveals specific metabolites and metabolic pathways linked to ICI-induced irAEs, providing potential biomarkers for early prediction and new insights into irAEs pathogenesis to optimize clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.